Insider · CIK 0001872219
Jean Bennett
Files at IRD (Ocuphire Pharma, Inc.), RGNX (REGENXBIO Inc.). First filing -, latest -.
In brief
Jean Bennett files SEC Form 4 as director at IRD (Ocuphire Pharma, Inc.), and also at RGNX (REGENXBIO Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Jean Bennett has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 11 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 29, 2026 | RGNX REGENXBIO Inc. | AGrant or award Common Stock | +9,807 | $0.00 | $0 | 28,861 | Jun 2, 2026 |
| May 29, 2026 | RGNX REGENXBIO Inc. | AGrant or award Stock Options (Right to Buy)derivative | +46,600 | $0.00 | $0 | 46,600 | Jun 2, 2026 |
| Apr 20, 2026 | IRD Ocuphire Pharma, Inc. | AGrant or award Common Stock | +24,367 | $0.00 | $0 | 259,019 | Apr 22, 2026 |
| Jan 1, 2026 | IRD Ocuphire Pharma, Inc. | AGrant or award Common Stock | +21,127 | - | - | 234,652 | Jan 5, 2026 |
| May 30, 2025 | RGNX REGENXBIO Inc. | AGrant or award Common Stock | +7,768 | $0.00 | $0 | 19,054 | Jun 3, 2025 |
| May 30, 2025 | RGNX REGENXBIO Inc. | AGrant or award Stock Options (Right to Buy)derivative | +39,815 | $0.00 | $0 | 39,815 | Jun 3, 2025 |
| Apr 30, 2025 | IRD Ocuphire Pharma, Inc. | AGrant or award Common Stock | +79,504 | $0.00 | $0 | 213,525 | May 2, 2025 |
| Apr 30, 2025 | IRD Ocuphire Pharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +79,592 | $0.00 | $0 | 79,592 | May 2, 2025 |
| Jan 2, 2025 | IRD Ocuphire Pharma, Inc. | AGrant or award Common Stock | +34,021 | - | - | 134,021 | Jan 6, 2025 |
| Oct 22, 2024 | IRD Ocuphire Pharma, Inc. | AGrant or award Common Stock | +100,000 | $0.00 | $0 | 100,000 | Oct 24, 2024 |
| Oct 22, 2024 | IRD Ocuphire Pharma, Inc. | AGrant or award Stock Option (right to buy)derivative | +172,874 | $0.00 | $0 | 172,874 | Oct 24, 2024 |
Questions about Jean Bennett
Answered from the filings on this page, as of the latest one.
Is Jean Bennett buying or selling?
Jean Bennett has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Jean Bennett's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Jean Bennett has 0.
Where does Jean Bennett file Form 4?
Jean Bennett has filed Form 4 at IRD (Ocuphire Pharma, Inc.); RGNX (REGENXBIO Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.